Literature DB >> 23095259

Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.

Antonios Bayas1, Ralf Gold, Markus Naumann.   

Abstract

Lewis-Sumner syndrome (LSS, synonymous multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is a dysimmune peripheral neuropathy responding to corticosteroids and intravenous immunoglobulins (IVIG) in the majority of patients. We report on the long term treatment (37 and 46months respectively) of two LSS patients, who had initially responded to IVIG, with subcutaneous immunoglobulins (SCIg). Both were switched to SCIg since stabilization by IVIG could only be achieved with short treatment intervals, and one of them also suffered from recurrent transient ischemic attacks (TIAs) following IVIG related increased blood viscosity. Long-term use of SCIg was safe and well tolerated. Both patients were clinically stable with only mild to moderate fluctuations requiring SCIg dosage adaptions. No further ischemic events occurred, when the patient was switched to SCIg.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095259     DOI: 10.1016/j.jns.2012.09.033

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Use of immunoglobulin (Ig) in peripheral neuropathies. Impact of Ig on remission rates: comparison of intravenous immunoglobulin and subcutaneous immunoglobulin.

Authors:  M-S Yoon
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 2.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

3.  Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders.

Authors:  Min-Suk Yoon; Ralf Gold; Antonios Kerasnoudis
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

4.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

Authors:  Ivo N van Schaik; Nan van Geloven; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath; Ingemar S J Merkies
Journal:  Trials       Date:  2016-07-25       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.